Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses

Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses

Abstract Background Shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to rem...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Rodrigo Alonso-Navarro, Margarita Ramírez, Mar Masiá, Roger Paredes, Rocío Montejano, Marina Povar-Echeverria, Jordi Carratalà, Miguel Salavert, Enrique Bernal, Carlos Dueñas, Juan Flores, Francisco Fanjul, Isabel Gutiérrez, Verónica Rico, Lourdes Mateu, Julen Cadiñanos, Juan Berenguer, Alex Soriano
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	BMC 2023-05-01
Sraith:	BMC Infectious Diseases
Ábhair:	SARS-CoV-2 Remdesivir Days from symptoms onset ICU Progression
Rochtain ar líne:	https://doi.org/10.1186/s12879-023-08222-y

Míreanna comhchosúla

Remdesivir administration for SARS-CoV-2 pneumonia in ICU and non-ICU patients: outcome and posttreatment differences — the Italian Military Hospital experience
de réir: Antonio Sabba, et al.
Foilsithe / Cruthaithe: (2023-09-01)

The effect of remdesivir on mortality and the outcome of patients with COVID‐19 in intensive care unit: A case–control study
de réir: Mehran Amirizadeh, et al.
Foilsithe / Cruthaithe: (2023-11-01)

The use of Remdesivir in pregnant women with COVID-19
de réir: Gulbanu Shaimerdenova, et al.
Foilsithe / Cruthaithe: (2023-02-01)

Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven
de réir: Richard D. Shih, et al.
Foilsithe / Cruthaithe: (2020-12-01)

Publicaciones sobre hidroxicloroquina y remdesivir: actualización septiembre 2020
de réir: Flor álvarez de Toledo
Foilsithe / Cruthaithe: (2020-10-01)

Publicaciones sobre hidroxicloroquina y remdesivir: actualización septiembre 2020
de réir: Flor álvarez de Toledo
Foilsithe / Cruthaithe: (2020-10-01)

Use of Remdesivir in children with COVID-19: report of an Italian multicenter study
de réir: Lorenza Romani, et al.
Foilsithe / Cruthaithe: (2024-02-01)

Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study
de réir: Emiel Leegwater, et al.
Foilsithe / Cruthaithe: (2023-10-01)

Efficacy and Safety of Remdesivir in COVID-19 Positive Dialysis Patients
de réir: Batool Butt, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Remdesivir prescription in pregnant women infected with COVID-19: A report of compassionate use
de réir: Azam Zafarbakhsh, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Prominent bradycardia in a COVID-19 patient receiving Remdesivir: a case report
de réir: Sidhi Laksono Purwowiyoto, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Clinical outcomes and considerations in outpatient with COVID‐19 receiving remdesivir therapy
de réir: Zeinab Siami, et al.
Foilsithe / Cruthaithe: (2024-07-01)

Remdesivir in a pregnant patient with COVID-19 pneumonia
de réir: Ranadheer Dande, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Critical reappraisal of remdesivir investigational trials in COVID-19
de réir: P. Brouqui, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Remdesivir versus standard-of-care for severe Coronavirus disease 2019 Infection: an analysis of 28-day mortality
de réir: Olender, Susan A., et al.
Foilsithe / Cruthaithe: (2022)

Adverse effects of remdesivir for the treatment of acute COVID-19 in the pediatric population: a retrospective observational study
de réir: Abigail Schulz, et al.
Foilsithe / Cruthaithe: (2024-02-01)

Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia: A case report
de réir: José A Gonzales-Zamora, et al.
Foilsithe / Cruthaithe: (2020-08-01)

The journey of remdesivir: from Ebola to COVID-19
de réir: Joe Pardo, et al.
Foilsithe / Cruthaithe: (2020-05-01)

Measuring the energy for the molecular graphs of antiviral agents: Hydroxychloroquine, Chloroquine and Remdesivir
de réir: Muhammad Haroon Aftab, et al.
Foilsithe / Cruthaithe: (2024-01-01)

Mucocutaneous adverse effects of remdesivir and favipiravir in patients with Covid-19 infection: A systematic review
de réir: Pradeep Balasubramanian, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections
de réir: S. Saqrane, et al.
Foilsithe / Cruthaithe: (2021-05-01)

Presentation of vitiligo in a case of COVID‐19 infection concomitant with receiving remdesivir
de réir: Farideh Beyki, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System
de réir: Concetta Rafaniello, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics
de réir: Bhaswati Chatterjee, et al.
Foilsithe / Cruthaithe: (2022-05-01)

Remdesivir – Current evidence & perspective in management of COVID-19 infection
de réir: Jyoti Bajpai, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Chitosan-Based Nanocarriers for Delivery of Remdesivir
de réir: Viktoria Milkova, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Remdesivir-induced severe hypoglycemia in an elderly man without diabetes: a case report
de réir: Yasunori Nagano, et al.
Foilsithe / Cruthaithe: (2025-01-01)

Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources
de réir: Lianne Barnieh, et al.
Foilsithe / Cruthaithe: (2023-05-01)

Remdesivir effects on COVID-19 infection in adult patients
de réir: Zena Hasan Sahib, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Hospital at home treatment with remdesivir for patients with COVID-19: real-life experience
de réir: Irene Pereta, et al.
Foilsithe / Cruthaithe: (2023-02-01)

Clinical outcomes of remdesivir-treated COVID-19 patients in South Korea
de réir: Mi Yu, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Remdesivir in renal transplant patients with coronavirus disease 2019: An observational study
de réir: Muzamil Latief, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy
de réir: Pierluigi Russo, et al.
Foilsithe / Cruthaithe: (2022-05-01)

Synthesis of Radioisotope 14C Labelled Remdesivir
de réir: Zhi-yang YU, et al.
Foilsithe / Cruthaithe: (2025-02-01)

Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
de réir: Alexandra A. Taube, et al.
Foilsithe / Cruthaithe: (2020-09-01)

Differential cytokine responses in hospitalized COVID-19 patients limit efficacy of Remdesivir
de réir: Chan, Yi-Hao, et al.
Foilsithe / Cruthaithe: (2022)

Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
de réir: Ivan Gentile, et al.
Foilsithe / Cruthaithe: (2023-12-01)

The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
de réir: Ganghee Chae, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Adjusted green spectrophotometric determination of favipiravir and remdesivir in pharmaceutical form and spiked human plasma sample using different chemometric supported models
de réir: Mohamed S. Imam, et al.
Foilsithe / Cruthaithe: (2023-07-01)

Perbandingan Angka Kematian Terapi Antiviral Favipiravir dan Remdesivir pada Pasien COVID-19 Di RSUP Dr. Sardjito Yogyakarta
de réir: Nova Satriyani, et al.
Foilsithe / Cruthaithe: (2023-01-01)